Literature DB >> 22257103

Changes in the levels of thioredoxin and indoleamine-2,3-dioxygenase activity in plasma of patients with colorectal cancer treated with chemotherapy.

Monica Cavia-Saiz1, Pilar Muñiz, Reyes De Santiago, Marta Herreros-Villanueva, Carlos Garcia-Giron, Ana Sofia Lopez, Maria Jesus Coma-Del Corral.   

Abstract

Increased oxidative stress and indoleamine-2,3-dioxygenase (IDO) activity have been reported in cancer, but their relationship with chemotherapy remains unknown. The aim of the present study was to examine wether the chemotherapy treatments used in colorectal cancer had an additional effect on oxidative stress and on IDO activity. Plasma samples were collected from 27 colorectal cancer patients on cytostatic treatment, 27 with cytostatic drugs plus monoclonal antibodies (cytostatic-Mabs) and 15 non-treated patients. All patients with colorectal cancer had high plasma malondialdehyde (MDA), thioredoxin (Trx) levels, and elevated IDO activity in plasma (IDOp) and in dendritic cells (IDOc). This study shows that treatment with cytostatics have an effect on oxidative stress by increasing MDA levels and by decreasing Trx levels and IDO activity. However, treatment with cytostatic-Mabs showed no effect on MDA levels but decreased Trx levels, and the IDO activity showed values similar to the healthy group. Significant correlations between plasma IDO activity and the levels of Trx (r = 0.2062, p < 0.05) and MDA (r = 0.2873, p < 0.005) were observed. Furthermore, our study suggests that IDO activity measured as kynurenine levels could be used as a marker of the response to the chemotherapy treatments, although further studies are necessary.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22257103     DOI: 10.1139/o11-077

Source DB:  PubMed          Journal:  Biochem Cell Biol        ISSN: 0829-8211            Impact factor:   3.626


  4 in total

1.  The role of plasma IDO activity as a diagnostic marker of patients with colorectal cancer.

Authors:  M Cavia-Saiz; P Muñiz Rodríguez; B Llorente Ayala; M García-González; M J Coma-Del Corral; C García Girón
Journal:  Mol Biol Rep       Date:  2014-01-17       Impact factor: 2.316

2.  IDO Immune Status after Chemoradiation May Predict Survival in Lung Cancer Patients.

Authors:  Weili Wang; Lei Huang; Jian-Yue Jin; Shruti Jolly; Yong Zang; Huanmei Wu; Li Yan; Wenhu Pi; Lang Li; Andrew L Mellor; Feng-Ming Spring Kong
Journal:  Cancer Res       Date:  2017-11-08       Impact factor: 12.701

3.  Indoleamine 2,3-dioxygenase activity and clinical outcome following induction chemotherapy and concurrent chemoradiation in Stage III non-small cell lung cancer.

Authors:  Ben C Creelan; Scott Antonia; Gerold Bepler; Timothy J Garrett; George R Simon; Hatem H Soliman
Journal:  Oncoimmunology       Date:  2013-03-01       Impact factor: 8.110

Review 4.  What is the prospect of indoleamine 2,3-dioxygenase 1 inhibition in cancer? Extrapolation from the past.

Authors:  Yu Yao; Heng Liang; Xin Fang; Shengnan Zhang; Zikang Xing; Lei Shi; Chunxiang Kuang; Barbara Seliger; Qing Yang
Journal:  J Exp Clin Cancer Res       Date:  2021-02-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.